GlassScriptPhysician profile
Abul K Abbas
NPI 1881652964
$57,603.17
in general payments reported to CMS, 2019-2025
5 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $5,325 · 2021: $12K · 2022: $21K · 2024: $2,358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,357.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb Sa | $18,300.00 | 2021-2022 | |
| Celgene Corporation | $16,666.67 | 2019 | |
| Sarepta Therapeutics, INC. | $12,317.50 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $9,119.00 | 2020-2022 | |
| Ptc Therapeutics, INC. | $1,200.00 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abul Abbas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.